Literature DB >> 31851796

A Successful Trial for Lupus - How Good Is Good Enough?

Jane E Salmon1, Timothy B Niewold1.   

Abstract

Mesh:

Substances:

Year:  2019        PMID: 31851796     DOI: 10.1056/NEJMe1915490

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  The winter of my discontent.

Authors:  Hasan Yazıcı
Journal:  Turk Arch Pediatr       Date:  2021-05-01

Review 2.  Type I interferon in the pathogenesis of systemic lupus erythematosus.

Authors:  Mariana Postal; Jessica F Vivaldo; Ruth Fernandez-Ruiz; Jacqueline L Paredes; Simone Appenzeller; Timothy B Niewold
Journal:  Curr Opin Immunol       Date:  2020-11-24       Impact factor: 7.486

Review 3.  Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment.

Authors:  François Chasset; Jean-Michel Dayer; Carlo Chizzolini
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

Review 4.  Type I interferon antagonists in clinical development for lupus.

Authors:  Jacqueline L Paredes; Timothy B Niewold
Journal:  Expert Opin Investig Drugs       Date:  2020-09-01       Impact factor: 6.206

Review 5.  Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach.

Authors:  Marlene Plüß; Silvia Piantoni; Chris Wincup; Peter Korsten
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.